Stay tuned and follow the latest
developments and news in Molecular Oncology.
Genekor’s Pathology Laboratory now offers the Claudin 18.2 (CLDN 18.2) test, used to administer Zolbetuximab in combination with chemotherapy for patients with advanced or metastatic gastric adenocarcinoma and gastroesophageal junction […]
Read More
The FRα test is performed for the administration of mirvetuximab soravtansine and is aimed at patients with platinum-resistant ovarian cancer who are FRα-positive and have received 1-3 lines of therapy. […]
Read More
The application of next-generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of developing new malignancies. The […]
Read More
Genekor announces the opening of our new pathology laboratory. Genekor’s experienced and qualified staff is here to provide you with the most reliable and valid results to enhance your efforts […]
Read More
Genekor participated again this year in the European Human Genetics Conference 2024 held in Berlin, where Dr. Konstantinos Agiannitopoulos, Molecular Biologist, Ph.D and Group Leader of Genekor’s Hereditary Cancer Group, […]
Read More
Breast cancer remains the most common type of cancer among women worldwide and remains the leading cause of death. Neuroendocrine breast cancer (NBC), a rare subtype that occurs in less […]
Read More
There are rapid developments in the field of early diagnosis of many cancers. Pioneering molecular tests, which also use AI, are now available in our country and can change the […]
Read More
Genekor Medical S.A. actively participated in the 2-day Scientific Meeting on Cardiac Amyloidosis and Genetic Cardiopathies on April 19 and 20 at the Cotsen Auditorium of the American School of […]
Read More
We feel joy and pride that “The Smile of the Child” was awarded for its humanitarian work and its contribution to the health sector. Our partnership began in 2022, with […]
Read More